11646

協賛企業

Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).

著者 Durrie DS , Kennard MG , Boghossian AJ
Adv Ther.2007 Nov-Dec ; 24(6):1278-85.
この記事をPubMed上で見るPubMedで表示

Durrie Vision, Overland Park, Kansas 66211, USA. ddurrie@durrievision.com

(16view , 0users)
The present study, which was designed as a prospective, double-masked, randomized, controlled, single-site study, was conducted to compare the effects of 3 approved ophthalmic nonsteroidal anti-inflammatory drugs-nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc., Fort Worth, Tex), ketorolac tromethamine ophthalmic solution 0.4% (Acular LS; Allergan, Irvine, Calif), and bromfenac 0.09% (Xibromtrade mark; ISTA Pharmaceuticals, Irvine, Calif)-on corneal reepithelialization and postoperative pain control in patients undergoing photorefractive keratectomy. In addition to nonsteroidal anti-inflammatory drugs, each patient received an antibiotic-moxifloxacin hydrochloride ophthalmic solution 0.5% (nepafenac group) or gatifloxacin ophthalmic solution 0.3% (ketorolac and bromfenac groups). All treatments were administered 3 times daily beginning 1 d preoperatively and continuing for 1 wk postoperatively; prednisolone acetate 1.0% was administered concurrently 4 times daily. Bandage contact lenses were replaced at each postoperative visit for corneal staining and epithelial defect grading. Self-evaluation of pain relief was recorded on postoperative days 1 and 3 with the use of a visual analog scale. A total of 29 patients (58 eyes) were enrolled and underwent bilateral custom photorefractive keratectomy. Mean time to reepithelialization was 5.50+/-1.59 d for the nepafenac 0.1% group, 5.62+/-1.23 d for the ketorolac 0.4% group, and 7.25+/-2.53 d for the bromfenac 0.09% group. A significant difference was detected between nepafenac 0.1% and bromfenac 0.09% and between ketorolac 0.4% and bromfenac 0.09% (P<.05). Significant reductions in pain scores were observed with nepafenac 0.1% on day 1 (-1.13) and day 3 (-1.32), ketorolac 0.4% on day 3 (-0.88), and bromfenac 0.09% on day 3 (-0.83). No adverse events were reported. Eyes treated with nepafenac 0.1% or ketorolac 0.4% achieved complete reepithelialization significantly faster than those treated with bromfenac 0.09%. Daily contact lens removal and application of fluorescein may have delayed reepithelialization in the overall population; however, the effect would have been the same in all 3 groups. Pain relief with nepafenac 0.1% was achieved sooner than with ketorolac 0.4% or bromfenac 0.09%.
PMID: 18165210 [PubMed - indexed for MEDLINE]
保存論文に追加 保存論文に追加

論文ランキング

週間人気論文ランキング - 閲覧数 (2010/07/24/ 09時更新)

Effects of bacterial toxins on endothelial tight junction in vitro: a mechanism-based investigation.

先週: 1位 ranksame 245view,2users 保存 要約を見る 要約

Prognostic impact of metastatic lymph node ratio on gastric cancer after curative distal gastrectomy.

先週: 3位 rankup 182view,0users 保存 要約を見る 要約

Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.

先週: 8位 rankup 78view,11users 保存 要約を見る 要約

Personality disorders and biosocial trait theories: The argument for radical legal reform.

先週: 2位 rankdown 76view,2users 保存 要約を見る 要約

The differentiation of rat adipose-derived stem cells into OEC-like cells on collagen scaffolds by co-culturing with OECs.

先週: 9位 rankup 68view,11users 保存 要約を見る 要約

Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).

先週: 5位 rankdown 68view,0users 保存 要約を見る 要約

Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts.

先週: 7位 ranksame 64view,1users 保存 要約を見る 要約

A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.

先週: 10位 rankup 34view,28users 保存 要約を見る 要約

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

先週: 6位 rankdown 34view,0users 保存 要約を見る 要約

An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

先週: 4位 rankdown 30view,0users 保存 要約を見る 要約
※view数:週間 user数:合計